Insiders · AUPH

AUPH insider transactions

Aurinia Pharmaceuticals Inc (AUPH) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for AUPH

• 13h
  SEC Form 4 filed by Director Johnson Craig A

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 13h
  SEC Form 4 filed by Director Goetz Kathleen

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 13h
  SEC Form 4 filed by Director Nova Tina Susan

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 13h
  SEC Form 4 filed by Director Bailey Jeffrey Allen

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 6d
  Chief Executive Officer Tang Kevin bought $12,455,227 worth of shares (814,606 units at $15.29) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 19d
  Chief Legal Officer Robertson Stephen P. was granted 115,541 shares, increasing direct ownership by 23% to 621,402 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 19d
  Chief Financial Officer Hearne Michael S was granted 116,144 shares (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 19d
  Chief Operating Officer Cole Ryan was granted 116,144 shares (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 67d
  SEC Form 3 filed by new insider Cole Ryan

  3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 67d
  SEC Form 3 filed by new insider Hearne Michael S

  3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 90d
  SVP, Chief Medical Officer Keenan Greg covered exercise/tax liability with 8,069 shares, decreasing direct ownership by 5% to 154,449 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 97d
  Director Tang Kevin bought $12,688,806 worth of shares (900,000 units at $14.10) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 97d
  Chief Operating Officer Donley Matthew Maxwell covered exercise/tax liability with 40,761 shares and was granted 58,160 shares, increasing direct ownership by 3% to 680,299 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 97d
  EVP, General Counsel Robertson Stephen P. was granted 59,090 shares and covered exercise/tax liability with 36,525 shares, increasing direct ownership by 5% to 505,861 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 97d
  SVP, Chief Medical Officer Keenan Greg was granted 40,586 shares, increasing direct ownership by 33% to 162,518 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 97d
  Chief Financial Officer Miller Joseph M was granted 57,229 shares and covered exercise/tax liability with 37,511 shares, increasing direct ownership by 4% to 576,421 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 97d
  Chief Executive Officer Greenleaf Peter was granted 196,403 shares and covered exercise/tax liability with 100,890 shares, increasing direct ownership by 5% to 1,840,379 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 105d
  Chief Operating Officer Donley Matthew Maxwell covered exercise/tax liability with 32,901 shares, decreasing direct ownership by 5% to 662,900 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 105d
  Chief Executive Officer Greenleaf Peter covered exercise/tax liability with 100,171 shares, decreasing direct ownership by 5% to 1,744,866 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 105d
  Chief Financial Officer Miller Joseph M covered exercise/tax liability with 32,424 shares, decreasing direct ownership by 6% to 556,703 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 105d
  EVP, General Counsel Robertson Stephen P. covered exercise/tax liability with 34,638 shares, decreasing direct ownership by 7% to 483,296 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 125d
  SVP, Chief Medical Officer Keenan Greg covered exercise/tax liability with 11,552 shares, decreasing direct ownership by 9% to 121,932 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 154d
  EVP, General Counsel Robertson Stephen P. was granted 48,558 shares and covered exercise/tax liability with 40,385 shares, increasing direct ownership by 2% to 517,934 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 154d
  Chief Operating Officer Donley Matthew Maxwell was granted 54,166 shares and covered exercise/tax liability with 42,787 shares, increasing direct ownership by 2% to 695,801 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 154d
  Chief Financial Officer Miller Joseph M was granted 49,038 shares and covered exercise/tax liability with 40,161 shares, increasing direct ownership by 2% to 589,127 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 154d
  Chief Executive Officer Greenleaf Peter was granted 165,384 shares and covered exercise/tax liability with 113,169 shares, increasing direct ownership by 3% to 1,845,037 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 196d
  Director Bailey Jeffrey Allen covered exercise/tax liability with 2,716 shares, decreasing direct ownership by 11% to 22,775 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 196d
  Director Johnson Craig A covered exercise/tax liability with 6,039 shares, decreasing direct ownership by 29% to 14,592 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 307d
  Director Tang Kevin bought $13,590,000 worth of shares (1,300,000 units at $10.45) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 307d
  Chief Medical Officer Keenan Greg sold $210,000 worth of shares (20,000 units at $10.50), decreasing direct ownership by 13% to 133,484 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 388d
  SEC Form 4 filed by Director Nova Tina Susan

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 388d
  SEC Form 4 filed by Director Johnson Craig A

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 388d
  SEC Form 4 filed by Director Goetz Kathleen

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 388d
  SEC Form 4 filed by Director Bailey Jeffrey Allen

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 388d
  SEC Form 3 filed by new insider Nova Tina Susan

  3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 388d
  SEC Form 3 filed by new insider Goetz Kathleen

  3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 458d
  Chief Medical Officer Keenan Greg sold $68,350 worth of shares (8,305 units at $8.23), decreasing direct ownership by 5% to 153,484 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 461d
  Chief Executive Officer Greenleaf Peter was granted 624,433 shares and sold $2,871,124 worth of shares (360,540 units at $7.96), increasing direct ownership by 17% to 1,788,945 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 461d
  Chief Medical Officer Keenan Greg was granted 62,583 shares and sold $97,912 worth of shares (12,239 units at $8.00), increasing direct ownership by 45% to 161,789 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 461d
  Chief Financial Officer Miller Joseph M sold $939,612 worth of shares (118,013 units at $7.96) and was granted 196,168 shares, increasing direct ownership by 16% to 577,361 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 461d
  EVP, General Counsel Robertson Stephen P. was granted 186,512 shares and sold $975,223 worth of shares (122,479 units at $7.96), increasing direct ownership by 14% to 509,276 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 461d
  Chief Operating Officer Donley Matthew Maxwell was granted 218,348 shares and sold $994,425 worth of shares (124,893 units at $7.96), increasing direct ownership by 16% to 680,465 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 461d
  Director Tang Kevin bought $12,713,126 worth of shares (1,600,000 units at $7.95) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 546d
  Director Tang Kevin bought $10,822,000 worth of shares (1,200,000 units at $9.02) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 560d
  Director Smith Karen L. was granted 12,135 shares, increasing direct ownership by 96% to 24,807 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 560d
  Director Leversage Jill was granted 12,135 shares, increasing direct ownership by 94% to 25,053 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 560d
  Director Johnson Craig A was granted 20,631 shares (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 560d
  Director Bailey Jeffrey Allen was granted 12,135 shares, increasing direct ownership by 91% to 25,491 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 560d
  Director Jayne David R.W. was granted 12,135 shares, increasing direct ownership by 27% to 56,499 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 573d
  Director Bailey Jeffrey Allen converted options into 17,913 shares and sold $38,416 worth of shares (4,557 units at $8.43) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 573d
  Director Smith Karen L. converted options into 17,913 shares and sold $44,182 worth of shares (5,241 units at $8.43) (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 573d
  New insider Keenan Greg claimed ownership of 111,445 shares (SEC Form 3)

  3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 573d
  SEC Form 3 filed by new insider Johnson Craig A

  3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 623d
  New insider Tang Kevin claimed ownership of 7,229,500 shares (SEC Form 3)

  3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 626d
  SEC Form 4 filed by Former Director Mackay-Dunn R. Hector

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 669d
  Chief Commercial Officer Habig Scott Michael sold $96,902 worth of shares (18,249 units at $5.31), decreasing direct ownership by 4% to 456,338 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 747d
  Balakrishnan Brinda sold $2,985 worth of shares (520 units at $5.74), decreasing direct ownership by 3% to 17,523 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 747d
  Billen Daniel sold $30,146 worth of shares (5,252 units at $5.74), decreasing direct ownership by 16% to 28,141 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 747d
  Jayne David R.W. sold $28,390 worth of shares (4,946 units at $5.74), decreasing direct ownership by 10% to 44,364 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
• 747d
  Leversage Jill sold $32,201 worth of shares (5,610 units at $5.74), decreasing direct ownership by 30% to 12,918 units (SEC Form 4)

  4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)